Affiliation:
1. Liver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital , Boston, Massachusetts , USA
Abstract
Abstract
Infection with chronic hepatitis C virus (HCV) is an important risk factor for hepatocellular carcinoma (HCC). Direct-acting antiviral therapy has transformed care for patients with HCV and reduces the risk of HCC. Despite HCV cure, a residual HCC risk remains in patients with advanced fibrosis and cirrhosis, with multiple mechanisms underlying subsequent hepatocarcinogenesis. Transcriptomic and proteomic signatures demonstrate the capacity for HCC risk stratification, and chemoprevention strategies are emerging. For now, pending more precise stratification, HCC surveillance of patients with cured HCV and advanced fibrosis or cirrhosis should continue.
Funder
National Institutes of Health
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Immunology and Allergy